Jupiter Neurosciences (JUNS) is trading down at $2.50 (-3.47%), as of the latest quote. It operates in the Health Care sector.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | — | $0 | $21.8K |
| Gross profit | — | — | $17.6K |
| Gross margin | — | — | 80.6% |
| Operating income | −$3.87M | −$3.09M | −$8.91M |
| Operating margin | — | — | −40873.2% |
| Net income | −$4.78M | −$2.44M | −$8.64M |
| Net margin | — | — | −39662.8% |
| EPS (diluted) | −$0.18 | −$0.08 | −$0.25 |
| Balance sheet | |||
| Cash and equivalents | $28.5K | $3.77M | $3.79M |
| Total assets | $148.6K | $6.20M | $5.56M |
| Total liabilities | $5.95M | $2.03M | $7.40M |
| Shareholders' equity | −$5.80M | $4.17M | −$1.83M |
| Cash flow | |||
| Operating cash flow | −$481.0K | −$3.91M | −$5.41M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | — | — | — | $18.7K | $24.2K |
| Gross profit | — | — | — | — | — | — | $14.3K | $21.1K |
| Gross margin | — | — | — | — | — | — | 76.6% | 86.9% |
| Operating income | −$493.5K | −$1.47M | −$1.54M | −$2.26M | −$2.30M | −$2.81M | −$1.96M | −$2.74M |
| Operating margin | — | — | — | — | — | — | −10524.3% | −11313.4% |
| Net income | −$591.0K | −$1.53M | −$1.53M | −$2.25M | −$2.29M | −$2.58M | −$2.06M | −$2.27M |
| Net margin | — | — | — | — | — | — | −11054.9% | −9380.9% |
| EPS (diluted) | −$0.02 | −$0.05 | −$0.05 | −$5.09 | −$0.07 | $4.96 | −$0.06 | −$4.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $253 | $3.77M | $2.71M | $1.88M | $723.8K | $3.79M | $2.36M | $1.52M |
| Total assets | $85.5K | $6.20M | $4.96M | $3.97M | $2.58M | $5.56M | $3.95M | $3.72M |
| Total liabilities | $5.84M | $2.03M | $1.90M | $2.63M | $2.52M | $7.40M | $6.73M | $4.08M |
| Shareholders' equity | −$5.75M | $4.17M | $3.06M | $1.34M | $57.4K | −$1.83M | −$2.78M | −$366.0K |
| Cash flow | ||||||||
| Operating cash flow | −$42.6K | −$3.70M | −$1.06M | −$828.2K | −$1.15M | −$2.37M | −$1.43M | −$2.29M |
From Jupiter Neurosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Jupiter Neurosciences in our feed yet.